サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1556568

腫瘍微小環境市場レポート：2030年までの動向、予測、競合分析

Tumor Microenvironment Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

腫瘍微小環境市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年08月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

腫瘍微小環境の動向と予測

世界の腫瘍微小環境市場は、2024年から2030年にかけてCAGR 11.2％で成長すると予測されます。この市場の主な促進要因は、がん罹患率の上昇、免疫腫瘍学における腫瘍微小環境の重要性の高まり、さらに政府と製薬企業が腫瘍学研究への投資を強化していることです。世界の腫瘍微小環境市場の将来は、バイオ製薬会社、病院、診断検査室、研究機関、CROの各市場における機会によって有望視されています。

セグメント別腫瘍微小環境

本調査では、世界の腫瘍微小環境について、がんの種類別、製品別、治療法別、最終用途別、地域別の予測を掲載しています。

腫瘍微小環境市場の洞察

Lucintelは、予測期間中も肺がんが最大のセグメントであり続けると予測しています。

同市場では、バイオ医薬品企業が引き続き最大セグメントとなります。

北米は、最新技術の導入が進んでいること、ライフサイエンス研究のための政府からの資金援助、大手製薬企業やバイオテクノロジー企業が進出していることなどから、予測期間中も最大地域であり続けるでしょう。

よくある質問

Q1.市場の成長予測は：

A1.世界の腫瘍微小環境市場は、2024年から2030年にかけてCAGR 11.2％で成長すると予想されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、がんの有病率の上昇、免疫腫瘍学における腫瘍微小環境の重要性の高まり、そして政府や製薬企業が腫瘍学研究への投資を強化していることです。

Q3.市場の主要セグメントは：

A3.世界の腫瘍微小環境市場の将来は、バイオ医薬品会社、病院、診断検査室、研究機関、CROの各市場における機会によって有望視されています。

Q4.市場の主要企業は：

A4.主要な腫瘍微小環境企業は以下の通りです：

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、予測期間中、肺がんが最大のセグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.北米は、最新技術の導入が進んでいること、ライフサイエンス研究に対する政府からの資金援助、大手製薬企業やバイオテクノロジー企業が進出していることから、予測期間中も最大地域であり続けると思われます。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の腫瘍微小環境市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の腫瘍微小環境市場の動向（2018～2023年）と予測（2024～2030年）
  • がんの種類別世界腫瘍微小環境市場
    • 肺がん
    • 大腸がん
    • 乳がん
    • 前立腺がん
    • 膀胱がん
    • その他
  • 製品別の腫瘍微小環境市場
    • T細胞
    • 腫瘍関連マクロファージ
    • 骨髄由来抑制細胞
    • がん関連線維芽細胞
    • 制御性T細胞
    • その他
  • 治療法別の腫瘍微小環境市場
    • モノクローナル抗体
    • サイトカイン
    • がんワクチン
    • 腫瘍溶解性ウイルス
    • 養子細胞療法
    • その他
  • 最終用途別世界腫瘍微小環境市場
    • バイオ医薬品企業
    • 病院
    • 診断検査室
    • 調査機関
    • CRO (医薬品開発業務受託機関)
    • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

  • 世界の腫瘍微小環境市場：地域別
  • 北米の腫瘍微小環境市場
  • 欧州の腫瘍微小環境市場
  • アジア太平洋の腫瘍微小環境市場
  • その他地域の腫瘍微小環境市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • がんの種類別の世界の腫瘍微小環境市場の成長機会
    • 製品別の世界の腫瘍微小環境市場の成長機会
    • 治療法別の世界の腫瘍微小環境市場の成長機会
    • 最終用途別の世界の腫瘍微小環境市場の成長機会
    • 地域別の世界の腫瘍微小環境市場の成長機会
  • 世界の腫瘍微小環境市場における新たな動向
  • 戦略分析
    • 新製品開発
    • 世界の腫瘍微小環境市場の能力拡大
    • 世界の腫瘍微小環境市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN
目次

Tumor Microenvironment Trends and Forecast

The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets. The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Tumor Microenvironment by Segment

The study includes a forecast for the global tumor microenvironment by cancer type, product, therapy, end use, and region.

Tumor Microenvironment Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Others

Tumor Microenvironment Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • T Cells
  • Tumor-Associated Macrophages
  • Myeloid-Derived Suppressor Cells
  • Cancer-Associated Fibroblasts
  • Regulatory T Cells
  • Others

Tumor Microenvironment Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Monoclonal Antibodies
  • Cytokines
  • Cancer Vaccines
  • Oncolytic Viruses
  • Adoptive Cell Therapies
  • Others

Tumor Microenvironment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Biopharmaceutical Companies
  • Hospital
  • Diagnostic Laboratories
  • Research Institutes
  • Contract Research Organizations
  • Others

Tumor Microenvironment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Tumor Microenvironment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tumor microenvironment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tumor microenvironment companies profiled in this report include-

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Tumor Microenvironment Market Insights

Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Within this market, biopharmaceutical company will remain the largest segment.

North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Features of the Global Tumor Microenvironment Market

Market Size Estimates: Tumor microenvironment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Tumor microenvironment market size by cancer type, product, therapy, end use, and region in terms of value ($B).

Regional Analysis: Tumor microenvironment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, product, therapy, end use, and regions for the tumor microenvironment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tumor microenvironment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for tumor microenvironment market?

Answer: The global tumor microenvironment market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the tumor microenvironment market?

Answer: The major drivers for this market are rising prevalence of cancer, emerging importance of the tumor microenvironment in immuno-oncology, along with the governments and pharmaceutical corporations boosting their investments in oncology research.

Q3. What are the major segments for tumor microenvironment market?

Answer: The future of the global tumor microenvironment market looks promising with opportunities in the biopharmaceutical company, hospital, diagnostic laboratory, research institute, and contract research organization markets.

Q4. Who are the key tumor microenvironment market companies?

Answer: Some of the key tumor microenvironment companies are as follows:

  • Thermo Fisher Scientific
  • Illumina
  • Danaher
  • Merck
  • BD Biosciences
  • Promega
  • Bio-Techne
  • Bio-Rad Laboratories
  • Hoffmann-La Roche
  • QIAGEN

Q5. Which tumor microenvironment market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer will remain the largest segment over the forecast period.

Q6. In tumor microenvironment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high adoption of modern technology, funding from the government for life science research, and the presence of big pharmaceutical and biotech corporations in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the tumor microenvironment market by cancer type (lung cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, and others), product (T cells, tumor-associated macrophages, myeloid-derived suppressor cells, cancer-associated fibroblasts, regulatory t cells, and others), therapy (monoclonal antibodies, cytokines, cancer vaccines, oncolytic viruses, adoptive cell therapies, and others), end use (biopharmaceutical companies, hospital, diagnostic laboratories, research institutes, contract research organizations, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Tumor Microenvironment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Tumor Microenvironment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Tumor Microenvironment Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Colorectal Cancer
    • 3.3.3: Breast Cancer
    • 3.3.4: Prostate Cancer
    • 3.3.5: Bladder Cancer
    • 3.3.6: Others
  • 3.4: Global Tumor Microenvironment Market by Product
    • 3.4.1: T Cells
    • 3.4.2: Tumor-Associated Macrophages
    • 3.4.3: Myeloid-Derived Suppressor Cells
    • 3.4.4: Cancer-Associated Fibroblasts
    • 3.4.5: Regulatory T Cells
    • 3.4.6: Others
  • 3.5: Global Tumor Microenvironment Market by Therapy
    • 3.5.1: Monoclonal Antibodies
    • 3.5.2: Cytokines
    • 3.5.3: Cancer Vaccines
    • 3.5.4: Oncolytic Viruses
    • 3.5.5: Adoptive Cell Therapies
    • 3.5.6: Others
  • 3.6: Global Tumor Microenvironment Market by End Use
    • 3.6.1: Biopharmaceutical Companies
    • 3.6.2: Hospital
    • 3.6.3: Diagnostic Laboratories
    • 3.6.4: Research Institutes
    • 3.6.5: Contract Research Organizations
    • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Tumor Microenvironment Market by Region
  • 4.2: North American Tumor Microenvironment Market
    • 4.2.1: North American Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.2.2: North American Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.3: European Tumor Microenvironment Market
    • 4.3.1: European Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.3.2: European Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.4: APAC Tumor Microenvironment Market
    • 4.4.1: APAC Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.4.2: APAC Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others
  • 4.5: ROW Tumor Microenvironment Market
    • 4.5.1: ROW Tumor Microenvironment Market by Cancer Type: Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer, and Others
    • 4.5.2: ROW Tumor Microenvironment Market by End Use: Biopharmaceutical Companies, Hospital, Diagnostic Laboratories, Research Institutes, Contract Research Organizations, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Tumor Microenvironment Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Tumor Microenvironment Market by Product
    • 6.1.3: Growth Opportunities for the Global Tumor Microenvironment Market by Therapy
    • 6.1.4: Growth Opportunities for the Global Tumor Microenvironment Market by End Use
    • 6.1.5: Growth Opportunities for the Global Tumor Microenvironment Market by Region
  • 6.2: Emerging Trends in the Global Tumor Microenvironment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Tumor Microenvironment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tumor Microenvironment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Thermo Fisher Scientific
  • 7.2: Illumina
  • 7.3: Danaher
  • 7.4: Merck
  • 7.5: BD Biosciences
  • 7.6: Promega
  • 7.7: Bio-Techne
  • 7.8: Bio-Rad Laboratories
  • 7.9: Hoffmann-La Roche
  • 7.10: QIAGEN